Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status approved; investigational
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 65015-756; 49702-203; 60687-362; 53873-075; 49702-205; 69097-167; 42385-714; 52482-003; 70966-0036; 0173-0663; 65862-055; 60505-3252; 65862-026; 69097-166; 53873-073; 55773-0589; 68554-0043; 31722-001; 49702-204; 64380-710; 68554-0016; 31722-752; 31722-754; 50742-624; 60687-720; 64380-711; 68180-602; 53104-7677; 70159-001; 31722-753; 54838-566; 57237-274; 60429-354; 66993-478; 68180-603; 53104-7538; 65015-701; 67835-0017; 60505-3250; 0904-6583; 53873-074; 65862-577; 33342-001; 0173-0662; 60505-3251; 65862-259; 65862-025; 82245-0204; 33342-002; 50742-623; 60429-353
UNII 2T8Q726O95
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vertigo17.02.12.002; 04.04.01.003--
Viral infection11.05.04.001--Not Available
Visual acuity reduced06.02.10.012; 17.17.01.0110.001012%
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.001012%Not Available
Fat redistribution14.08.04.002--Not Available
Joint range of motion decreased15.01.02.0060.001012%
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.005; 11.07.01.018; 10.01.01.0340.001012%Not Available
Hypoacusis04.02.01.006--
Localised oedema08.01.07.011; 14.05.06.009; 02.05.04.006--
Lipodystrophy acquired23.07.01.003; 14.08.04.0080.002024%Not Available
Intervertebral disc protrusion15.10.01.0040.001012%Not Available
Lipase13.05.01.011--Not Available
Ear discomfort04.03.01.005--Not Available
Lymphatic disorder01.09.01.003--Not Available
Diastolic dysfunction02.04.02.0220.001012%Not Available
Fanconi syndrome acquired20.05.03.012; 14.01.01.0130.002024%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Mitochondrial toxicity12.03.01.009; 14.11.02.0010.001012%Not Available
Affect lability19.04.01.001--Not Available
Body fat disorder14.08.04.012--Not Available
Foetal death18.01.02.003; 08.04.01.0110.002530%
Nail pigmentation23.02.05.007--Not Available
Vasodilation procedure25.03.01.001--Not Available
Bone metabolism disorder15.02.03.009; 14.04.04.0090.001012%Not Available
Drug resistance08.06.01.0050.122642%Not Available
Urine output increased13.13.03.002--Not Available
Neurological symptom17.02.05.0100.001012%Not Available
Adverse event08.06.01.0100.003036%Not Available
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages